Among 16,352 propensity-score-matched adults with comorbid asthma and type 2 diabetes, tirzepatide (a dual GIP/GLP-1 receptor agonist) and semaglutide (a selective GLP-1 RA) produced virtually identical 12-month asthma exacerbation rates — 11.0% versus 11.1%, hazard ratio 1.00 (95% CI: 0.91–1.10). However, tirzepatide was associated with an 8% lower risk of short-acting beta-agonist (SABA) use (HR 0.92; 95% CI: 0.88–0.96), while systemic corticosteroid use was comparable between arms.
The finding lands at a meaningful intersection: GLP-1 receptor agonists have attracted growing interest in pulmonology for their anti-inflammatory properties, weight-reduction effects, and potential to reduce airway hyperreactivity — all mechanistically relevant in obesity-driven asthma. The hypothesis that tirzepatide's additional GIP receptor engagement might confer added respiratory benefit was scientifically plausible but goes unconfirmed here for hard exacerbation endpoints. The subtle SABA reduction, while statistically significant in this large cohort, requires cautious interpretation: SABA use is a softer, more behaviorally influenced endpoint than hospitalization or oral corticosteroid-defined exacerbations.
Critical limitations include the study's retrospective, observational design using TriNetX claims data, which risks residual confounding despite propensity matching — particularly for medication adherence, obesity severity, and inhaler technique. Causal inference remains impossible. This is nonetheless confirmatory and clinically reassuring: clinicians selecting between these agents for T2D management need not prioritize one over the other solely on asthma grounds. Randomized trials stratified by obesity status and asthma phenotype are the essential next step.